Biologics In Focus - January 2025

Welcome to the January edition of Biologics in Focus, our monthly newsletter showcasing the latest highlights and innovations in the biologics industry.

This month, dive into mRNA and LNP capabilities at our Geleen Center of Excellence, gain insights from real-world ADC manufacturing strategies, and discover advancements in bispecific antibody development. Don’t miss our press highlights, $368M oncology breakthroughs, and upcoming events shaping the industry. Stay ahead with expert webinars and cutting-edge discussed innovations.

Insights and Analysis

mRNA and LNP Encapsulation Capabilities at our Geleen/NL Center of Excellence

Watch the video and discover why our Geleen Center of Excellence is the ideal partner for mRNA and LNP development. This video showcases our end-to-end services, including proprietary platforms, in-house analytics, and cGMP manufacturing capabilities. See how we streamline projects from research to commercialization with rapid tech transfers and cutting-edge technologies.

Charting a Successful CMC Journey for Your ADC Drug Product

This webinar delves into the best practices for optimizing bioconjugate drug product tech transfers and supplies during clinical and commercial phases. We present real-world case studies that showcase innovative solutions to accelerate clinical tech transfers, supported by science-driven development approaches. Additionally, we discuss tailored strategies for various entry points, whether as stand-alone services or integrated bioconjugate drug substance and drug product solutions.

Considerations for Successful Tech Transfer of a Biologics Upstream Process

This article examines the critical factors for successful tech transfer of biologics upstream processes. We discuss how product lifecycle stages and molecular formats influence the approach, risks, and outcomes. By understanding these aspects, we highlight the importance of a structured, modular strategy to ensure consistency, scalability, and risk management throughout the process.

Lonza in the Press

Q&A: Robust Supply Chains and Global Networks are Among Key Considerations When Choosing an mRNA CDMO

Explore the critical factors in selecting an mRNA CDMO, including the importance of robust supply chains and global networks. Gain insights from industry experts on overcoming manufacturing challenges, fostering regulatory relationships, and leveraging technological innovations to enhance drug development and production. This article offers valuable guidance for making informed decisions in the evolving mRNA therapeutics landscape.

The Benefit of Technological Advancements to BsAb Development

Explore how technological advancements are revolutionizing bispecific antibody (BsAb) development and enhancing cancer immunotherapy. This article delves into innovations like artificial intelligence in design, high-throughput production techniques, and the emergence of bispecific antibody-drug conjugates (BsADCs), highlighting their potential to improve efficacy and safety in treatments.

Elevation Lifts HER3 ADC Toward Clinic with $368M Synaffix Deal

Elevation Oncology has entered into a licensing agreement with Synaffix, valued at up to $368 million, to develop EO-1022, a novel HER3-targeting antibody-drug conjugate (ADC) for treating HER3-expressing solid tumors. This collaboration leverages Synaffix's proprietary ADC technologies to enhance cancer therapy development.

Key Upcoming Events

View more events

Upcoming Webinars

Thursday, 13 February 2025. 11am EST | 5pm CET

Producing Engineered Extracellular Vesicles with a Platform Approach

Thank you for reading. Remember to subscribe so you never miss our monthly updates.

If you'd like to find out more about Lonza Biologics, you can visit our website or contact one of our team of experts.